Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

LAVAL, QC, Jan. 14 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it will conclude enrolment next month for the Canadian-European pivotal trial of its cartilage repair device, BST-CarGel(R). To date, the Company has enrolled more than 70 subjects and participating clinical sites will be permitted to enrol additional subjects until February 10th, 2009.

"With the certainty provided by this date, we are now sure that the final results from this pivotal trial will be available in the first quarter of 2010, once the last treated subject has completed their twelve-month follow up period. Furthermore, we are confident that the current number of enrolled subjects already represents a sufficiently powered study and that with this data we can meet the overall objectives of the study," said Michel Lagueux, Chairman of the Board of Directors. "At the same time, we remain sensitive to the fact that there are eligible individuals who still want a chance to participate in the study and we will work closely with our investigators over the next four weeks to ensure that as many as possible can be enrolled."

"I am very proud to be involved in the clinical development of this important new therapy in what is the largest randomized clinical trial for cartilage repair ever conducted in North America. Enrolment was certainly the greatest challenge, given our adherence to strict subject eligibility criteria, but in the end this rigour will ensure trial data of the highest quality and integrity," said Dr. William Stanish, Professor of Surgery at Dalhousie University in Halifax, Nova Scotia, and Principal Investigator for the trial.

Mr. Lagueux continued, "BioSyntech would like to acknowledge the team of over 25 orthopaedic surgeons and their support staff for their sincere dedication and perseverance in achieving this enrolment milestone."

This randomized trial compares the treatment of cartilage lesions using BST-CarGel(R) applied following microfracture to treatment with microfracture alone. The trial is enrolling subjects aged 18 to 55 years of age with focal cartilage lesions less than 10 cm2 located on the femoral condyles of the knee. Subjects are further stratified by their lesion type, either characterized as acute (i.e. traumatic) or chronic (i.e. degenerative). The primary endpoint for this trial is cartilage repair at twelve months, defined by the quantity and quality of the repaired tissue as measured with quantitative magnetic resonance imaging (MRI). Secondary endpoints are safety and knee-related pain, stiffness and function as measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. Results from this study are intended to support marketing applications in Canada and Europe.

About BioSyntech

BioSyntech is a medical device company specialized in the development, manufacturing and commercialization of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's platform technology is a family of hydrogels called BST-Gel(R), some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. For additional information, visit www.biosyntech.com.

Forward-Looking Statements

This press release contains forward-looking statements and information which are subject to material risks and uncertainties. Such statements are not historical facts and are based on the current expectations of management. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com. These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumstance or otherwise, except in accordance with law.


'/>"/>
SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017 Illustris Pharmaceuticals, ... to launch its revolutionary delivery technology platform.  The leadership ... of Medicis, Mark Prygocki , former President of ... S. K. Tan , founding member of Derma-Rx ... in aesthetics and cosmeceuticals in Asia ...
(Date:3/1/2017)... ... 2017 , ... At interpack 2017, held in Düsseldorf, Germany ... quality can help food and pharmaceutical manufacturers improve processes and increase competitiveness in ... to vision inspection and metal detection – will be on display, as well ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... manufacturing technology for use in filling injectable drug products into vials, syringes, and ... SA25 robotic work-cell . CEO of Singota Solutions Alisa Wright expressed the importance ...
(Date:2/28/2017)... Calif. , Feb. 28, 2017   Sienna ... and aesthetics company, is pleased to announce that ... advisor to Sienna,s CEO and Board of Directors. Dr. ... and chief executive officer of Allergan for 17 years. ... return to dermatology and aesthetics. "I look ...
Breaking Biology Technology:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):